We are proud to announce the incorporation of Nioside® Launch into our Pulmonology Division.
This treatment is indicated for:
- Idiopathic pulmonary fibrosis (IPF) in adults.
- Other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
- Slowing the rate of lung function decline in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
- A rare and complex condition, for which Nioside® provides a reliable therapeutic option.
Available presentations:
- Soft capsules of 100 mg and 150 mg.
With the launch of Nioside®, at Aspen Laboratorios we reaffirm our commitment to research, development, and the availability of innovative medicines for diseases that require specialized care.